^
Association details:
Biomarker:KRAS G13D
Cancer:Colorectal Cancer
Drug:MEN1611 (PI3K inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations

Excerpt:
...colorectal cancer HCT116, harboring both PIK3CA and KRAS mutations, showed strong tumor growth inhibition by CH5132799, consistent with our in vitro observations.
DOI:
10.1158/1078-0432.CCR-10-2882